| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
- |
| Employees |
1 |
| Revenues (TTM) (Millions $) |
223 |
| Net Income (TTM) (Millions $) |
0 |
| Cash Flow (TTM) (Millions $) |
119 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Amryt Pharma Plc is a biopharmaceutical company based in Dublin, Ireland, with a focus on developing treatments for rare and orphan diseases. The company was founded in 2015 and has since then been dedicated to pursuing innovative treatments for diseases that are often overlooked by larger pharmaceutical companies.
The company's main focus is on developing treatments for a range of diseases, including epidermolysis bullosa, acromegaly, and Cushing's syndrome, which are all rare or orphan diseases with limited treatment options available. Amryt Pharma Plc has a global presence, with offices in Europe and the United States, from where they have been able to make significant progress in the development of important new drugs.
Amryt Pharma Plc operates through three main subsidiaries: Amryt Healthcare, a commercial operation that focuses on launching and distributing high-quality medicines in Europe; Amryt Pharma US, the company's recently established U.S. subsidiary that is responsible for clinical development, regulatory approval, and commercial launch of products in the United States; and Cutanea Life Sciences, which focuses on developing treatments for rare dermatological diseases.
The company has a number of proprietary products in its portfolio, including Lojuxta, a treatment for adult patients with homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder that causes high levels of bad cholesterol in the blood. Lojuxta has been approved for marketing by the European Medicines Agency (EMA) since 2013 and is available in more than 20 countries around the world.
Another important product in Amryt Pharma Plc's portfolio is Myalepta, a treatment for generalized lipodystrophy, a rare disorder that causes the loss of fat tissue throughout the body. Myalepta has been approved for use in Europe since 2014 and is currently under review by the U.S. Food and Drug Administration (FDA).
Recently, the company has been making progress in the development of a treatment for epidermolysis bullosa (EB), a rare genetic disorder that causes the skin to blister and slough off easily. This debilitating condition has limited treatment options and no cure, making Amryt Pharma Plc's progress in this area all the more important.
Overall, Amryt Pharma Plc is a company with a clear mission and a strong focus on developing innovative treatments for rare and orphan diseases. The company's proprietary products, global presence, and commitment to research and development position it well for continued growth and success in the biopharmaceutical industry.
Company Address: Dept 920a 196 High Road London 0
Company Phone Number: 1518 0200 Stock Exchange / Ticker: NASDAQ AMYT
|
%